Carl Zeiss Meditec/€AFX

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Carl Zeiss Meditec

Carl Zeiss Meditec AG, publicly traded under the ticker symbol AFX, specializes in the healthcare technology sector. Founded in 2002 as a spin-off from Carl Zeiss AG, it provides comprehensive medical solutions for ophthalmology and microsurgery. Operating globally, the company combines its expertise in optics, electronics, and precision engineering to offer innovative products that enhance patient care and clinical outcomes.

Ticker

€AFX

Primary listing

XETRA

Industry

Health Care Equipment & Supplies
Headquarters

Employees

5,713

AFX Metrics

BasicAdvanced
€5.1B
32.95
€1.77
1.23
€0.60
1.03%

What the Analysts think about AFX

Analyst ratings (Buy, Hold, Sell) for Carl Zeiss Meditec stock.

Bulls say / Bears say

The acquisition of DORC contributed €99.9 million to the Ophthalmology Strategic Business Unit, indicating successful expansion into the retinal surgery market. (zeiss.com)
The approval of the VISUMAX® 800 refractive laser system for the Chinese market is expected to drive significant growth in the region. (zeiss.com)
The company has implemented stringent cost control measures, reducing operating expenses below €200 million for the first time in two years, which is expected to strengthen margin recovery. (seat11a.com)
The company experienced a decline in revenue of -1.1% in fiscal year 2023/24, with adjusted EBIT falling to €245.9 million from €362.9 million the previous year, indicating financial struggles. (zeiss.com)
Analysts have issued a 'Sell' rating due to anticipated difficulties in upcoming fiscal years and the necessity for significant restructuring to achieve a more favorable outlook. (markets.businessinsider.com)
The Microsurgery strategic business unit generated revenue of €477.0 million, a decline of -7.0%, mainly due to weak neurosurgery business and investment reluctance in North America. (zeiss.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

AFX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AFX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €AFX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs